{
    "clinical_study": {
        "@rank": "71", 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the effect of anakinra (IL-1 ra) and pegsunercept\n      (PEG sTNF-RI) when they are used together in improving the signs and symptoms of rheumatoid\n      arthritis.  The study will also evaluate the safety of the combination treatment and its\n      effect on slowing down bone and joint destruction due to rheumatoid arthritis.  The results\n      will be compared to the effect when only 1 single medication (anakinra or pegsunercept) is\n      used."
        }, 
        "brief_title": "Evaluation of the Efficacy of Combination Treatment With Anakinra and Pegsunercept in Improving Rheumatoid Arthritis", 
        "completion_date": "December 2002", 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "-  diagnosed with rheumatoid arthritis for at least 6 months\n\n          -  must be taking methotrexate * must not take DMARDS other than methotrexate during the\n             study\n\n          -  must not have had previous treatment with and protein-based TNF-alpha inhibitor (eg.\n             etanercept, infliximab, PEG sTNF-RI, or D2E7)\n\n          -  must not have had previous treatment with anakinra\n\n          -  subjects must meet tender and swollen joint requirements at screening, have morning\n             stiffness, and/or have elevated acute phase reactants"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "May 20, 2002", 
        "id_info": {
            "nct_id": "NCT00037700", 
            "org_study_id": "20000198"
        }, 
        "intervention": [
            {
                "intervention_name": "anakinra", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "pegsunercept", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Interleukin 1 Receptor Antagonist Protein"
        }, 
        "lastchanged_date": "November 25, 2009", 
        "link": {
            "description": "AmgenTrials clinical trials website", 
            "url": "http://www.amgentrials.com"
        }, 
        "overall_official": {
            "affiliation": "Amgen", 
            "last_name": "MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "removed_countries": {
            "country": "United States"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00037700"
        }, 
        "responsible_party": {
            "name_title": "Global Development Leader", 
            "organization": "Amgen Inc."
        }, 
        "source": "Swedish Orphan Biovitrum", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Amgen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2001", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2007"
    }, 
    "geocoordinates": {}
}